Dr. Maron is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
41 Mall Rd
Burlington, MA 01805Phone+1 781-744-8000Fax+1 617-636-6204
Summary
- Martin Maron, MD, serves as the Director of the Hypertrophic Cardiomyopathy Center and the Co-Director of the Cardiac CT and MRI program at Tufts Medical Center and Associate Professor at Tufts University School of Medicine. His specialties include cardiac imagining, hypertrophic cardiomyopathy, and cardiac magnetic resonance imaging. He was the Hypertrophic Cardiomyopathy Association’s 2011 Clinician of the Year, and currently serves on the association’s Board of Directors. He is board certified in Cardiovascular Disease and Internal Medicine.
Education & Training
- Tufts Medical CenterFellowship, Cardiovascular Disease, 2002 - 2005
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2001
- Tulane University School of MedicineClass of 1999
Certifications & Licensure
- MA State Medical License 2002 - 2025
- NJ State Medical License 2013 - 2023
- FL State Medical License 2019 - 2021
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy Start of enrollment: 2007 Nov 01
- HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy Start of enrollment: 2014 Apr 01
- Extended ECG Monitoring in HCM Patients Start of enrollment: 2020 Jan 14
Publications & Presentations
PubMed
- 54 citationsEligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, a...Benjamin D Levine, Aaron L Baggish, Richard J Kovacs, Mark S Link, Martin S Maron
Journal of the American College of Cardiology. 2015-12-01 - 8 citationsCoexistence of acute takotsubo syndrome and acute coronary syndrome.Scott W. Sharkey, Ankur Kalra, Timothy D. Henry, Timothy D. Smith, Victoria R. Pink
Catheterization and Cardiovascular Interventions. 2020-10-01 - 8 citationsClinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis).Michael Butzner, Martin S. Maron, Phil Sarocco, Ethan J. Rowin, Chia-Chen Teng
The American Journal of Cardiology. 2021-09-06
Journal Articles
- Mini-Focus Issue: Hypertrophic Cardiomyopathy State-of-the-Art Review Clinical Spectrum and Management of Heart Failure in Hypertrophic CardiomyopathyMartin S Maron, Barry J Maron, James E Udelson, Ethan J Rowin, ScienceDirect
Lectures
- HCM and its Many Variations: When to Suspect and How to Diagnose?2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Other
- Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathyMaron MS, Elliott PM
http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-evaluation-of-hypertrophic-ca
UpToDate, Wolters Kluwer Health - 2012-12-13 - Overview of hypertrophic cardiomyopathy management including treatment of special problemsMaron MS
http://www.uptodate.com/contents/overview-of-hypertrophic-cardiomyopathy-management-including-treatm
UpToDate, Wolters Kluwer Health - 2012-12-06
Press Mentions
- Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic CardiomyopathyOctober 28th, 2024
- Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCMOctober 28th, 2024
- ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCMOctober 2nd, 2024
- Join now to see all
Grant Support
- Clinical And Therapeutic Implications Of Fibrosis In Hypertrophic CardiomyopathyNational Heart, Lung, And Blood Institute2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: